Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2023 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling. I need to check if the transcript shows management describing specific customers' or partners' growth trajectories as the driver of Tyson's own coming activity. Looking through the transcript, management discusses: - Macro conditions (Beef, Pork, Chicken market challenges) - Their own operational improvements, cost programs, capacity utilization - Their branded foods business performance - Customer relationships in general terms (Kantar rankings, fill rates) - The Williams Sausage acquisition The discussion of customers is mostly general - "winning with customers," "working more closely with customers," "building long-term supply partnerships." There's no specific narration of a particular customer's own expansion, ramp, or build-out that would drive Tyson's forward volumes. The growth narrative is about Tyson's own strategy, capacity, and market share gains. The counterparties mentioned (retailers, food service) are discussed in terms of Tyson's performance with them, not in terms of those parties' own trajectories driving Tyson's future. The Williams Sausage acquisition is about acquiring a business, not about a counterparty's growth. Management's forward account is about their own actions and macro conditions, not about reporting on someone else's expansion as the driver of their own.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.